Compare Rush Street Interactive Inc (RSI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rush Street Interactive Inc vs TG Therapeutics Inc — how do they compare? Rush Street Interactive Inc trades at $18.9 (market cap $2.35B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 3.5× Rush Street Interactive Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Rush Street Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rush Street Interactive Inc for 13 Days and TG Therapeutics Inc for 16 Days on average.
| RSI | TGTX | |
|---|---|---|
Market Cap | $2.35B | $8.16B |
Volume | 2,219,374 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.52 | $59.06 |
52-Week Low | $15.89 | $26.94 |
Typical Hold Time | 13 Days | 16 Days |
Enterprise Value | $2.01B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RSI (Rush Street Interactive) trades at $18.90, down 6.62% recently, with a bearish technical signal from moving averages. The company shows strong revenue growth from $1.13B in 2025 to $1.4B in 2026, though net income margin compressed to 2.33%. Recent Q2 2026 earnings beat expectations with EPS of $0.15 versus $0.1499 expected. Analyst consensus remains strongly bullish with 10 buy ratings and a $34.88 price target, representing 85% upside potential from current levels.
The stock presents significant upside based on analyst targets but faces execution risks amid competitive online gaming markets. High P/E ratio of 65.55 suggests premium valuation requiring sustained growth. Institutional interest remains strong with BlackRock's $448M investment in Q2 2026. Near-term performance hinges on Q3 earnings delivery and sports betting market expansion.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
